Gary P. Gamble

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

A. Gajra, M. Rooney, A. Tatum, 2002, Lung cancer.

The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.

A. Tatum, S. Graziano, N. Newman, 1994, Cancer research.

Prognostic Markers in Resected Non–Small-Cell Lung Cancer: An Patients with 5 Year Follow-Up

N. Weidner, J. Kern, S. Mehdi, 1999 .

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

M. Rooney, B. Poiesz, S. Graziano, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic markers in resected stage I and II non small-cell lung cancer: an analysis of 260 patients with 5 year follow-up.

N. Weidner, J. Kern, S. Mehdi, 1999, Clinical lung cancer.

Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

A. Gajra, S. Graziano, N. Newman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.

R. Govindan, M. Kelley, R. Christenson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular characterization of a large homozygous deletion in the small cell lung cancer cell line U2020: A strategy for cloning the putative tumor suppressor gene

K. Tory, M. Lerman, B. Zbar, 1992, Genes, chromosomes & cancer.

Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease.

A. Gajra, Ajeet Gajra, S. Graziano, 2003, Lung cancer.